1. 146 Alloantigen-specific Tr1 cells designed to prevent GvHD have a distinct molecular identity and suppress through CTLA-4 and PD-1. (9th November 2020) Authors: Cepika, Alma-Martina; Chen, Pauline P; Uyeda, Molly; Cieniewicz, Brandon; Narula, Mansi; Amaya, Laura; Louis, David M; Xu, Liwen; Ji, Xuhuai; Bertaina, Alice; Agarwal-Hashmi, Rajni; Davis, Mark M; Meyer, Everett; Bacchetta, Rosa; Roncarolo, Maria Grazia Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A88 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 146 Alloantigen-specific Tr1 cells designed to prevent GvHD have a distinct molecular identity and suppress through CTLA-4 and PD-1. (9th November 2020) Authors: Cepika, Alma-Martina; Chen, Pauline P; Uyeda, Molly; Cieniewicz, Brandon; Narula, Mansi; Amaya, Laura; Louis, David M; Xu, Liwen; Ji, Xuhuai; Bertaina, Alice; Agarwal-Hashmi, Rajni; Davis, Mark M; Meyer, Everett; Bacchetta, Rosa; Roncarolo, Maria Grazia Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A159 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗